|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 5 (March 1), 2000:
pp. 1709-1713
Hypofibrinogenemia in an individual with 2 coding ( 82
A G and B 235 PL) and 2 noncoding
mutations
Stephen O. Brennan,
Andrew P. Fellowes,
James M. Faed, and
Peter M. George
From the Molecular Pathology Laboratory, Canterbury Health
Laboratories, Christchurch Hospital, Christchurch, New Zealand, and
Blood Transfusion Service, Dunedin Hospital, Dunedin, New Zealand.
We investigated the molecular basis of hypofibrinogenemia in a man
with a normal thrombin clotting time. Protein analysis indicated equal
plasma expression of 2 different B alleles, and DNA
sequencing confirmed heterozygosity for a new B235 P L mutation. Protein analysis also revealed a novel  D chain, present
at a ratio of 1:2 relative to the A chain. Mass
spectrometry indicated a 14 d decrease in the
D-chain mass, and DNA sequencing showed this was
caused by a novel 82 AG substitution. DNA
sequencing established heterozygosity for 2 further mutations: TC in
intron 4 of the A gene and AC in the 3' noncoding region of
the B gene. Studies on the man's daughter, together with plasma
expression levels, discounted both the A and B mutations as the
cause of the low fibrinogen, suggesting that the 82 mutation caused
the hypofibrinogenemia. This was supported by analysis of 31 normal
controls in whom the B mutations were found at polymorphic levels,
with an allelic frequency of 5% for the B235 mutation and 42% for
the B 3' untranslated mutation. The 82 mutation was,
however, unique to the propositus. Residue 82 is located in the
triple helix that separates the E and D domains, and aberrant packing
of the helices may explain the decreased fibrinogen concentration.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. A. Morris, J. J. Marsh, P. G. Chiles, M. M. Magana, N.-C. Liang, X. Soler, D. J. DeSantis, D. Ngo, and V. L. Woods Jr
High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension
Blood,
August 27, 2009;
114(9):
1929 - 1936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Brennan, R. L. Davis, R. Lowen, and A. Ruskova
Deletion of five residues from the coiled coil of fibrinogen (B{beta} Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia
Haematologica,
April 1, 2009;
94(4):
585 - 588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Schmidt and S. O. Brennan
Modified Form of the Fibrinogen B{beta} Chain (des-Gln B{beta}), a Potential Long-Lived Marker of Pancreatitis
Clin. Chem.,
December 1, 2007;
53(12):
2105 - 2111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Okumura, F. Terasawa, H. Tanaka, M. Hirota, H. Ota, K. Kitano, K. Kiyosawa, and S. T. Lord
Analysis of fibrinogen gamma -chain truncations shows the C-terminus, particularly gamma Ile387, is essential for assembly and secretion of this multichain protein
Blood,
May 15, 2002;
99(10):
3654 - 3660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bolliger-Stucki, S. T. Lord, and M. Furlan
Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, A{alpha} R16C and {gamma} G165R
Blood,
July 15, 2001;
98(2):
351 - 357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Asselta, S. Duga, T. Simonic, M. Malcovati, E. Santagostino, P. L. F. Giangrande, P. M. Mannucci, and M. L. Tenchini
Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation
Blood,
October 1, 2000;
96(7):
2496 - 2500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Ploplis, J. Wilberding, L. McLennan, Z. Liang, I. Cornelissen, M. E. DeFord, E. D. Rosen, and F. J. Castellino
A Total Fibrinogen Deficiency Is Compatible with the Development of Pulmonary Fibrosis in Mice
Am. J. Pathol.,
September 1, 2000;
157(3):
703 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
